by Maria Zannes | Jan 7, 2026 | Press Releases
CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets gold standard for excellence across all laboratory service lines CAP accreditation reaffirms CyPath® Lung test’s...
by Maria Zannes | Dec 3, 2025 | Press Releases
SAN ANTONIO, Texas – December 3, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will...
by Maria Zannes | Nov 14, 2025 | Press Releases
Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet SAN ANTONIO, Texas – November 14, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of...
by Maria Zannes | Nov 5, 2025 | Press Releases
October test volume 111% more than 2025 year-to-date monthly average SAN ANTONIO, Texas — November 5, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today...
by Maria Zannes | Oct 28, 2025 | Press Releases
Australian patent strengthens global patent portfolio SAN ANTONIO, TX — October 28, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noninvasive test for lung...
by Maria Zannes | Oct 20, 2025 | Press Releases
Visit the CyPath® Lung team at Booth #2242 October 19-22 SAN ANTONIO, Texas – October 20, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...
